Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Fluidigm Corporation is a diagnostics & research business based in the US. Fluidigm Corporation shares (FLDM) are listed on the NASDAQ and all prices are listed in US Dollars. Fluidigm Corporation employs 627 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$5.80|
|52-week range||$3.71 - $10.10|
|50-day moving average||$6.03|
|200-day moving average||$5.46|
|Wall St. target price||$9.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.32|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-21)||N/A|
|1 month (2021-07-01)||-5.23%|
|3 months (2021-04-30)||15.77%|
|6 months (2021-01-28)||N/A|
|1 year (2020-07-28)||N/A|
|2 years (2019-07-28)||N/A|
|3 years (2018-07-28)||N/A|
|5 years (2016-07-28)||N/A|
Valuing Fluidigm Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Fluidigm Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Fluidigm Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.3. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Fluidigm Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$143.3 million|
|Gross profit TTM||$46.9 million|
|Return on assets TTM||-11.63%|
|Return on equity TTM||-42.25%|
|Market capitalisation||$547.2 million|
TTM: trailing 12 months
There are currently 7.5 million Fluidigm Corporation shares held short by investors – that's known as Fluidigm Corporation's "short interest". This figure is 0.7% up from 7.4 million last month.
There are a few different ways that this level of interest in shorting Fluidigm Corporation shares can be evaluated.
Fluidigm Corporation's "short interest ratio" (SIR) is the quantity of Fluidigm Corporation shares currently shorted divided by the average quantity of Fluidigm Corporation shares traded daily (recently around 741838.57566766). Fluidigm Corporation's SIR currently stands at 10.11. In other words for every 100,000 Fluidigm Corporation shares traded daily on the market, roughly 10110 shares are currently held short.
However Fluidigm Corporation's short interest can also be evaluated against the total number of Fluidigm Corporation shares, or, against the total number of tradable Fluidigm Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Fluidigm Corporation's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 Fluidigm Corporation shares in existence, roughly 100 shares are currently held short) or 0.1399% of the tradable shares (for every 100,000 tradable Fluidigm Corporation shares, roughly 140 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Fluidigm Corporation.
Find out more about how you can short Fluidigm Corporation stock.
We're not expecting Fluidigm Corporation to pay a dividend over the next 12 months.
Over the last 12 months, Fluidigm Corporation's shares have ranged in value from as little as $3.71 up to $10.0999. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Fluidigm Corporation's is 1.5734. This would suggest that Fluidigm Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. , as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.